Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

TAT Honorary Award

The TAT Honorary Award was established in the early 1990s to acknowledge distinguished cancer drug development experts who have devoted a major part of their careers to the discovery and development of better anticancer medicines.

The TAT Honorary Award is presented at the annual ESMO Targeted Anticancer Therapies (TAT) Congress and the Award recipient is invited to give a keynote lecture during the Opening Ceremony.

2022 TAT Honorary Award recipient

seymour-lesley

Lesley K Seymour, Director of the Investigational New Drug Program and Deputy Director of the Canadian Cancer Trials Group (CCTG), Professor of Oncology at Queens University, and medical oncologist at the Kingston Health Sciences Centre, Ontario, received the 2022 TAT Honorary Award in recognition of her outstanding contributions to early drug development and innovative clinical trial methodology.

Previous recipients of the TAT Honorary Award

  • Ruth Plummer (2021)
  • Lillian L. Siu (2020)
  • Geoffrey Shapiro (2019)
  • Jean-Charles Soria (2018)
  • Jedd Wolchok (2017)
  • Anthony W. Tolcher (2016)
  • Hilary Calvert (2015)
  • Patricia LoRusso (2014)
  • Jean-Pierre Armand (2013)
  • Elizabeth Eisenhauer (2012)
  • Giuseppe Giaccone (2011)
  • Axel Ullrich (2010)
  • Napoleone Ferrara (2009)
  • Julian Adams (2008)
  • Jaap Verweij (2007)
  • Paul Workman (2006)
  • Daniel Von Hoff (2005)
  • Bob Pinedo (2003)
  • John Mendelsohn (2002)

*No meeting took place in 2004

Nomination and selection process

The recipient is nominated by the TAT Congress Scientific Committee based on the following eligibility criteria.

The candidate must:

  • be a distinguished cancer drug development expert, who has devoted a major part of their career to the discovery and development of better anticancer medicines
  • demonstrate an affiliation to a major academic or cancer research / treatment institution
  • have published articles on drug development in highly cited peer-reviewed journals
  • be an ESMO member

The candidate must not:

Chairs of the current Scientific Committee may not be nominated. Members of the Scientific Committee are eligible however they may not nominate themselves. More than one nomination is allowed.

All nominations are evaluated and a final awardee is selected by the Selection Committee: the TAT Congress Scientific Committee Co-Chairs, the ESMO Nomination Committee Chair and the ESMO President.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.